Showing 101-120 of 214 for: Cochrane Systematic Reviews > Renal 
- HMG CoA reductase inhibitors (statins) for kidney transplant recipients
Cochrane Systematic Reviews, 27-Jan-2014
People with chronic kidney disease (CKD) have higher risks of cardiovascular disease compared to the general population. Specifically, cardiovascular deaths account most deaths in kidney transplant recipients. Statins are a potentially beneficial interven
- HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Cochrane Systematic Reviews, 8-Jul-2014
Cardiovascular disease (CVD) is the most frequent cause of death in people with early stages of chronic kidney disease (CKD), for whom the absolute risk of cardiovascular events is similar to people who have existing coronary artery disease. This is an up
- Human albumin for intradialytic hypotension in haemodialysis patients
Cochrane Systematic Reviews, 4-Oct-2010
Intradialytic hypotension (IDH) occurs in 20% to 55% of haemodialysis sessions and is more frequent among patients on long-term haemodialysis. Symptomatic IDH is generally defined as a decrease in systolic blood pressure (BP) of at least 10 mm Hg or a sys
- Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function
Cochrane Systematic Reviews, 17-Jul-2013
Hydroxyethyl starches (HES) are synthetic colloids commonly used for fluid resuscitation to replace intravascular volume, yet they have been increasingly associated with adverse effects on kidney function. This is an update of a Cochrane review first publ
- Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients
Cochrane Systematic Reviews, 17-Mar-2010
Cytomegalovirus (CMV) is the most common virus causing disease and death in solid organ transplant recipients during the first six months post-transplant. Previous systematic reviews have demonstrated the efficacy of antiviral medications used prophylacti
- Immunosuppressive agents for treating IgA nephropathy
Cochrane Systematic Reviews, 12-Mar-2020
IgA nephropathy is the most common glomerulonephritis world-wide. IgA nephropathy causes end-stage kidney disease (ESKD) in 15% to 20% of affected patients within 10 years and in 30% to 40% of patients within 20 years from the onset of disease. This is an
- Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome
Cochrane Systematic Reviews, 15-Nov-2021
Primary membranous nephropathy (PMN) is a common cause of nephrotic syndrome in adults. Without treatment, approximately 30% of patients will experience spontaneous remission and one third will have persistent proteinuria. Approximately one-third of patie
- Immunotherapy for advanced renal cell cancer
Cochrane Systematic Reviews, 29-Dec-2015
The course of advanced renal cell carcinoma is extremely variable, ranging from spontaneous remission to disease progression refractory to chemotherapy. Immunotherapy has held promise of improved outcomes based on uncontrolled studies and randomized contr
- Interleukin 2 receptor antagonists for kidney transplant recipients
Cochrane Systematic Reviews, 20-Jan-2010
Interleukin 2 receptor antagonists (IL2Ra) are used as induction therapy for prophylaxis against acute rejection in kidney transplant recipients. Use of IL2Ra has increased steadily since their introduction, but the proportion of new transplant recipients
- Intermittent catheter techniques, strategies and designs for managing long‐term bladder conditions
Cochrane Systematic Reviews, 26-Oct-2021
Intermittent catheterisation (IC) is a commonly recommended procedure for people with incomplete bladder emptying. Frequent complications are urinary tract infection (UTI), urethral trauma and discomfort during catheter use. Despite the many designs of in
- Intermittent versus continuous renal replacement therapy for acute renal failure in adults
Cochrane Systematic Reviews, 12-May-2008
Renal replacement therapy (RRT) for acute renal failure (ARF) can be applied intermittently (IRRT) or continuously (CRRT). It has been suggested that CRRT has several advantages over IRRT including better haemodynamic stability, lower mortality and higher
- Interventions for chronic abacterial prostatitis
Cochrane Systematic Reviews, 25-Oct-1999
Chronic abacterial prostatitis is a common disabling but enigmatic condition with a symptom complex of pelvic area pain and lower urinary tract symptoms. The scope of treatments recommended for chronic abacterial prostatitis is a testament to how little i
- Interventions for covert bacteriuria in children
Cochrane Systematic Reviews, 11-Jan-2012
Many studies investigating covert bacteriuria in children were conducted in the 1970s, but uncertainty remains about whether treatment is beneficial, because results are mixed in terms of treatment effectiveness. It is important to establish the effective
- Interventions for HIV‐associated nephropathy
Cochrane Systematic Reviews, 31-Jan-2013
Human immunodeficiency virus-associated nephropathy (HIVAN) is the most common cause of end stage kidney disease (ESKD) in human immunodeficiency virus-1 (HIV-1) serotype patients and it mostly affects patients of African descent. It rapidly progresses to
- Interventions for idiopathic steroid‐resistant nephrotic syndrome in children
Cochrane Systematic Reviews, 21-Nov-2019
The majority of children who present with their first episode of nephrotic syndrome achieve remission with corticosteroid therapy. Children who fail to respond to corticosteroids in the first episode of nephrotic syndrome (initial resistance) or develop r
- Interventions for metabolic bone disease in children with chronic kidney disease
Cochrane Systematic Reviews, 12-Nov-2015
Bone disease is common in children with chronic kidney disease (CKD) and when untreated may result in bone deformities, bone pain, fractures and reduced growth rates. This is an update of a review first published in 2010.
- Interventions for minimal change disease in adults with nephrotic syndrome
Cochrane Systematic Reviews, 1-Mar-2022
Steroids have been used widely since the early 1970s for the treatment of adult-onset minimal change disease (MCD). Recently, newer agents have been used in adult MCD aiming to reduce the risk of adverse effects. The response rates to immunosuppressive ag
- Interventions for paracetamol (acetaminophen) overdose
Cochrane Systematic Reviews, 23-Feb-2018
Paracetamol (acetaminophen) is the most widely used non-prescription analgesic in the world. Paracetamol is commonly taken in overdose either deliberately or unintentionally. In high-income countries, paracetamol toxicity is a common cause of acute liver
- Interventions for preventing and treating kidney disease in IgA vasculitis
Cochrane Systematic Reviews, 28-Feb-2023
IgA vasculitis (IgAV), previously known as Henoch-Schönlein purpura, is the most common vasculitis of childhood but may also occur in adults. This small vessel vasculitis is characterised by palpable purpura, abdominal pain, arthritis or arthralgia and ki
- Interventions for preventing bone disease in kidney transplant recipients
Cochrane Systematic Reviews, 22-Oct-2019
People who have chronic kidney disease (CKD) have important changes to bone structure, strength, and metabolism. Children experience bone deformity, pain, and delayed or impaired growth. Adults experience limb and vertebral fractures, avascular necrosis,
